TI
ADCT icon

Trexquant Investment’s ADC Therapeutics ADCT Stock Holding History

Trexquant Investment’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-46,985
Closed -$226K – 1333
2022
Q3 		$226K Buy
+46,985
New +$340K 0.01% 1142

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Trexquant Investment's ADCT Position: Q4 2022 in Review

Trexquant Investment sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 46,985 shares — an estimated $226K sold.

Trexquant Investment first reported a position in ADCT in Q3 2022 and held it in 1 quarter. The position peaked at $226K in Q3 2022. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

  • Trexquant Investment reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Trexquant Investment sold 46,985 ADC Therapeutics shares in Q4 2022, an estimated $226K.
  • Trexquant Investment first reported a position in ADC Therapeutics in Q3 2022 and held it in 1 quarter.
  • Trexquant Investment's ADC Therapeutics position peaked at $226K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on Trexquant Investment's 13F filing for Q4 2022, filed 13 Feb 2023.